Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CE7R CAR T cells |
Synonyms | |
Therapy Description |
CE7R CAR T cells are autologous T-cells that are engineered to express a CD171-targeted chimeric antigen receptor that contains CD28, CD3zeta, and 4-1-BB signaling domains as well as truncated EGFR, which potentially increases cytoxicity in CD171-expressing tumors (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CE7R CAR T cells | CD171 CAR+ T Cells|CD171-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T cells | CE7R CAR T cells are autologous T-cells that are engineered to express a CD171-targeted chimeric antigen receptor that contains CD28, CD3zeta, and 4-1-BB signaling domains as well as truncated EGFR, which potentially increases cytoxicity in CD171-expressing tumors (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02311621 | Phase I | CE7R CAR T cells | Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | Active, not recruiting | USA | 0 |